



5AU-1623
by

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By Linda M. Bunnell

ELI LILLY AND COMPANY

Date September 28, 1999

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Bunnell, et al.)
Serial No. : 09/163,769)
Filed : September 30, 1998) Group Art Unit:
For : 2-METHYL-THIENO-BENZODIAZEPINE) 1623 **RECEIVED**
FORMULATION) Examiner: OCT 04 1999
Docket No. : X-12542) XXXXX **TECH CENTER 1600/2900**

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Arlene Palmberg
Arlene Palmberg
Attorney for Applicants
Registration No. 40,422
Phone: 317-276-6015

Eli Lilly and Company
Patent Division/AP
Lilly Corporate Center
Indianapolis, IN 46285

September 27, 1999